methyl [7-chloro-5-(4-nitrobenzyl)imidazo[1,2-c]pyrimidin-8-yl]acetate | 862186-13-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并嘧啶类
• 英文名称: methyl [7-chloro-5-(4-nitrobenzyl)imidazo[1,2-c]pyrimidin-8-yl]acetate
• 英文别名: methyl 2-[7-chloro-5-[(4-nitrophenyl)methyl]imidazo[1,2-c]pyrimidin-8-yl]acetate
• CAS: 862186-13-8
• 化学式: C₁₆H₁₃ClN₄O₄
• 分子量: 360.757
• InChiKey: CKISXIKLMIJSIV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  25
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.19
• 拓扑面积：
  102
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  methyl [7-chloro-5-(4-nitrobenzyl)imidazo[1,2-c]pyrimidin-8-yl]acetate 在 乙醇 、 水 、 tin(ll) chloride 、 碳酸氢钠 作用下， 以 乙醇 、 水 、 乙酸乙酯 为溶剂， 反应 1.0h， 以92%的产率得到methyl [7-chloro-5-(4-aminobenzyl)imidazo[1,2-c]pyrimidin-8-yl]acetate
  参考文献：
  名称：

  [EN] IMIDAZO[1,2-C]PYRIMIDINYLACETIC ACID DERIVATIVES
  [FR] DERIVES D'ACIDE IMIDAZO[1,2-C]PYRIMIDINYLACETIQUE

  摘要：

  公开号：

  WO2005073234A3
• 作为产物：
  描述：

  methyl [4-chloro-6-[(2,2-dimethoxyethyl)amino]-2-(4-nitrobenzyl)pyrimidin-5-yl]acetate 在 三氟乙酸 、 三氟乙酸酐 作用下， 以 二氯甲烷 为溶剂， 反应 3.0h， 以25%的产率得到methyl [7-chloro-5-(4-nitrobenzyl)imidazo[1,2-c]pyrimidin-8-yl]acetate
  参考文献：
  名称：

  [EN] IMIDAZO[1,2-C]PYRIMIDINYLACETIC ACID DERIVATIVES
  [FR] DERIVES D'ACIDE IMIDAZO[1,2-C]PYRIMIDINYLACETIQUE

  摘要：

  公开号：

  WO2005073234A3

文献信息

• ISOTOPICALLY ENRICHED PYRIMIDIN-5-YL ACETIC ACID DERIVATIVES AS CRTH2 ANTAGONISTS
  申请人：Ly Tai Wei

  公开号：US20110172250A1

  公开（公告）日：2011-07-14

  Provided herein are 2 H- and 13 C-enriched compounds of formula (I) or (II); wherein R is as defined herein, and wherein at least one hydrogen atom, in certain embodiments, three or more hydrogen atoms, are deuterium atoms or at least one carbon atom is a carbon-13 atom. Also provided are pharmaceutical compositions and methods using the 2 H- and 13 C-enriched compounds, useful for treating CRTH2-related diseases or disorders such as, for example, asthma, allergic rhinitis, atopic dermatitis, allergic conjuvatitis, Churg-Strauss syndrome, sinusitis, basophilic leukemia, chronic urticaria or basophilic leukocytosis.

  本文提供了公式（I）或（II）的2H-和13C富集化合物；其中R如本文所定义，并且在某些情况下，至少一个氢原子，甚至三个或更多个氢原子，是氘原子，或者至少一个碳原子是碳-13原子。还提供了使用这些2H-和13C富集化合物的药物组合物和方法，用于治疗CRTH2相关疾病或疾病，例如哮喘、过敏性鼻炎、特应性皮炎、过敏性结膜炎、Churg-Strauss综合症、鼻窦炎、嗜碱性白血病、慢性荨麻疹或嗜碱性白细胞增多症。
• Imidazo[1,2-C]Pyrimidinylacetic Acid Derivatives
  申请人：Ly Tai-wei

  公开号：US20090012102A1

  公开（公告）日：2009-01-08

  The present invention relates to an imidazo[1,2-c]pyrimidinylacetic acid derivative and salts thereof which is useful as an active ingredient of pharmaceutical preparations. The imidazo[1,2-c]pyrimidinylacetic acid derivative of the present invention has excellent CRTH2 (G-protein-coupled chemoattractant receptor, expressed on Th2 cells) antagonistic activity and can be used for the prophylaxis and treatment of diseases associated with CRTH2 activity, in particular for the treatment of allergic diseases, such as asthma, allergic rhinitis, atopic dermatitis, and allergic conjunctivitis; eosinophil-related diseases, such as Churg-Strauss syndrome and sinusitis; basophil-related diseases, such as basophilic leukemia, chronic urticaria and basophilic leukocytosis in human and other mammals; and inflammatory diseases characterized by T lymphocytes and profuse leukocyte infiltrates such as psoriasis, eczema, inflammatory bowel disease, ulcerative colitis, Crohn's disease, COPD (chronic obstructive pulmonary disorder) and arthritis.

  本发明涉及一种咪唑[1,2-c]嘧啶基乙酸衍生物及其盐，其可用作制药制剂的活性成分。本发明的咪唑[1,2-c]嘧啶基乙酸衍生物具有优异的CRTH2（G蛋白偶联趋化因子受体，表达在Th2细胞上）拮抗活性，可用于预防和治疗与CRTH2活性相关的疾病，特别是用于过敏性疾病的治疗，如哮喘、过敏性鼻炎、特应性皮炎和过敏性结膜炎；嗜酸性粒细胞相关疾病，如Churg-Strauss综合征和鼻窦炎；嗜碱性粒细胞相关疾病，如嗜碱性白血病、慢性荨麻疹和人类及其他哺乳动物的嗜碱性白细胞增多症；以及以T淋巴细胞和大量白细胞浸润为特征的炎症性疾病，如牛皮癣、湿疹、炎症性肠病、溃疡性结肠炎、克罗恩病、慢性阻塞性肺疾病和关节炎。
• Imidazo[1,2-C]pyrimidinylacetic acid derivatives
  申请人：Actimis Pharmaceuticals, Inc.

  公开号：US07750014B2

  公开（公告）日：2010-07-06

  The present invention relates to an imidazo[1,2-c]pyrimidinylacetic acid derivative and salts thereof which is useful as an active ingredient of pharmaceutical preparations. The imidazo[1,2-c]pyrimidinylacetic acid derivative of the present invention has excellent CRTH2 (G-protein-coupled chemoattractant receptor, expressed on Th2 cells) antagonistic activity and can be used for the prophylaxis and treatment of diseases associated with CRTH2 activity, in particular for the treatment of allergic diseases, such as asthma, allergic rhinitis, atopic dermatitis, and allergic conjunctivitis; eosinophil-related diseases, such as Churg-Strauss syndrome and sinusitis; basophil-related diseases, such as basophilic leukemia, chronic urticaria and basophilic leukocytosis in human and other mammals; and inflammatory diseases characterized by T lymphocytes and profuse leukocyte infiltrates such as psoriasis, eczema, inflammatory bowel disease, ulcerative colitis, Crohn's disease, COPD (chronic obstructive pulmonary disorder) and arthritis.

  本发明涉及一种咪唑[1,2-c]嘧啶基乙酸衍生物及其盐，该衍生物可用作制药制剂的活性成分。本发明的咪唑[1,2-c]嘧啶基乙酸衍生物具有优异的CRTH2（表达于Th2细胞上的G蛋白偶联趋化因子受体）拮抗活性，可用于预防和治疗与CRTH2活性相关的疾病，特别是用于治疗过敏性疾病，如哮喘、过敏性鼻炎、特应性皮炎和过敏性结膜炎；嗜酸性粒细胞相关疾病，如Churg-Strauss综合征和鼻窦炎；嗜碱性粒细胞相关疾病，如嗜碱性白血病、慢性荨麻疹和人类及其他哺乳动物的嗜碱性白细胞增多症；以及以T淋巴细胞和大量白细胞浸润为特征的炎症性疾病，如牛皮癣、湿疹、炎症性肠病、溃疡性结肠炎、克罗恩病、慢性阻塞性肺疾病和关节炎。
• IMIDAZO 1,2-C PYRIMIDINYLACETIC ACID DERIVATIVES
  申请人：Actimis Pharmaceuticals, Inc.,

  公开号：EP1718649B1

  公开（公告）日：2009-06-10
• US7750014B2
  申请人：——

  公开号：US7750014B2

  公开（公告）日：2010-07-06